(firstQuint)Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES.

 This trial is a prospective, randomized, multi-center, open label, noninferiority trial.

 Patients undergoing PCI with DES will be eligible.

 After successful PCI with DES, all eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus P2Y12 antagonist following 3-month of DAPT.

.

 Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES@highlight

To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with DES.

